Asia-Pacific Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (B

Asia-Pacific Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (Bakery and Confectionery, Dairy and Frozen Desserts, Beverages, Sauces; Dressings; and Condiments, RTC and RTE Products, Meat; Poultry and Seafood, and Others)   

The APAC intravenous immunoglobulin market is expected to grow from US$ 2,609.61 million in 2022 to US$ 4,156.85 million by 2028. It is estimated to grow at a CAGR of 8.1% from 2022 to 2028.

Strong Pipeline Candidates for IVIG

Leading players in the intravenous immunoglobulin market have multiple projects, and many biological products in pipelines are based on proprietary technology. For instance, Evolve Biologics aims to manufacture and market plasma-derived therapeutics using its proprietary PlasmaCap EBA purification technology. The company is developing a portfolio of product candidates, IVIG, which completed its Phase III clinical trial in February 2021. Similarly, Biotest is a global company that offers plasma protein products and biotherapeutic drugs. The company is developing IgG Next Generation, a newly developed polyvalent immunoglobulin preparation for intravenous administration from human plasma to treat immunodeficiencies and autoimmune diseases. In September 2020, the company completed its phase III trial investigating IgG Next Generation for patients with primary immunodeficiency disease (PID). Thus, strong pipeline candidates for IVIG are expected to become a trend in the intravenous immunoglobulin market.

Market Overview

Asia Pacific (APAC) is the fastest-growing regional market for intravenous immunoglobulin. China, India, Japan, South Korea, Australia, and the Rest of APAC are the major contributors to the market in this region. Asia Pacific is likely to account for over 21.68% market share of the global intravenous immunoglobulin market in 2022 due to the increasing geriatric population, the rising prevalence of immune deficiency disorders, and the increasing adoption of immunoglobulin-based therapies for the treatment of primary immune deficiencies. Therefore, the region holds huge potential for the intravenous immunoglobulin market players to grow during the forecast period. China is a developing country in Asia Pacific with a well-established healthcare system and a fast-growing pharmaceutical industry. China is home to various medical, pharmaceutical, and biotechnology product manufacturing companies operating in the global market. China also has over 300 medical contract research organizations, along with prominent biopharmaceutical product manufacturers—including China Biologic Products Holdings, Inc. and Shanghai RAAS. These pharmaceutical companies are prone to global market competition, which encourages them to introduce innovative products, thereby boosting the growth of the intravenous immunoglobulin market.

APAC Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)

APAC Intravenous Immunoglobulin Market Segmentation

The APAC intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.

Based on application, the APAC intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022. Based on distribution channel, the APAC intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022. Based on end user, the APAC intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022. Based on country, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. China dominated the market in 2022. ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe lyophilized injectable market.
Highlights key business priorities to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe lyophilized injectable market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the lyophilized injectable market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution